GALT RSI Chart
Last 7 days
6.6%
Last 30 days
-4.4%
Last 90 days
85.6%
Trailing 12 Months
95.8%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 30, 2024 | zordani richard a. jr. | bought | 3,520 | 3.52 | 1,000 | - |
Apr 24, 2024 | lewis joel | bought | 3,390 | 3.39 | 1,000 | president and ceo |
Apr 23, 2024 | czirr james c | sold | -11,251 | 3.06 | -3,677 | - |
Apr 22, 2024 | czirr james c | sold | -65,248 | 3.06 | -21,323 | - |
Apr 22, 2024 | freeman kevin d | bought | 7,450 | 2.98 | 2,500 | - |
Apr 09, 2024 | freeman kevin d | acquired | - | - | 2,063 | - |
Mar 01, 2024 | lewis joel | sold | -299,065 | 1.96 | -152,584 | president and ceo |
Jan 24, 2024 | uihlein richard e | acquired | 40,000 | 1.72 | 23,256 | - |
Jan 16, 2024 | eldred kary | bought | 892 | 1.7858 | 500 | - |
Dec 29, 2023 | lewis joel | acquired | 19,266 | 1.66 | 11,606 | president and ceo |
Which funds bought or sold GALT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | Beacon Capital Management, LLC | unchanged | - | 11,235 | 57,133 | 0.01% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 8.93 | 31,859 | 87,916 | -% |
May 15, 2024 | SHEPHERD KAPLAN KROCHUK, LLC | unchanged | - | 8,760 | 28,680 | 0.02% |
May 15, 2024 | WEDBUSH SECURITIES INC | unchanged | - | 11,000 | 37,000 | -% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -9.62 | 13,877 | 59,944 | -% |
May 15, 2024 | Mariner, LLC | added | 160 | 49,766 | 67,823 | -% |
May 15, 2024 | 683 Capital Management, LLC | sold off | -100 | -184,318 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -23.73 | 1,200 | 13,429 | -% |
May 15, 2024 | BOOTHBAY FUND MANAGEMENT, LLC | sold off | -100 | -39,423 | - | -% |
May 15, 2024 | Squarepoint Ops LLC | new | - | 114,565 | 114,565 | -% |
Unveiling Galectin Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Galectin Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Galectin Therapeutics Inc News
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -8.2% | 26.00 | 28.00 | 22.00 | 20.00 | 20.00 | 21.00 | 18.00 | 26.00 | 34.00 | 42.00 | 38.00 | 33.00 | 23.00 | 30.00 | 34.00 | 41.00 | 44.00 | 48.00 | 51.00 | 53.00 | 8.00 |
Current Assets | -8.1% | 25.00 | 28.00 | 22.00 | 19.00 | 20.00 | 21.00 | 17.00 | 26.00 | 34.00 | 42.00 | 38.00 | 33.00 | 23.00 | 29.00 | 34.00 | 41.00 | 44.00 | 48.00 | 50.00 | 53.00 | 7.00 |
Cash Equivalents | -8.2% | 24.00 | 26.00 | 20.00 | 18.00 | 18.00 | 19.00 | 16.00 | 24.00 | 32.00 | 40.00 | 37.00 | 32.00 | 21.00 | 27.00 | 33.00 | 41.00 | 43.00 | 47.00 | 50.00 | 52.00 | 7.00 |
Net PPE | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liabilities | 9.7% | 97.00 | 88.00 | 73.00 | 71.00 | 63.00 | 53.00 | 40.00 | 41.00 | 40.00 | 39.00 | 29.00 | 16.00 | 5.00 | 5.00 | 3.00 | 4.00 | 1.00 | 3.00 | 1.00 | 1.00 | 1.00 |
Current Liabilities | -19.4% | 13.00 | 16.00 | 11.00 | 10.00 | 12.00 | 13.00 | 10.00 | 11.00 | 10.00 | 9.00 | 8.00 | 6.00 | 5.00 | 5.00 | 2.00 | 4.00 | 1.00 | 3.00 | 1.00 | 1.00 | 1.00 |
Shareholder's Equity | -17.5% | -72.81 | -61.96 | - | - | -44.37 | -33.92 | - | - | - | 1.00 | 8.00 | 15.00 | 17.00 | 22.00 | 30.00 | 35.00 | 41.00 | 44.00 | 48.00 | 50.00 | 5.00 |
Retained Earnings | -3.2% | -365 | -354 | -344 | -330 | -321 | -309 | -298 | -290 | -280 | -270 | -263 | -254 | -246 | -240 | -232 | -226 | -219 | -216 | -211 | -208 | -205 |
Additional Paid-In Capital | 0.2% | 292 | 292 | 291 | 277 | 276 | 275 | 274 | 273 | 272 | 271 | 270 | 270 | 262 | 262 | 261 | 261 | 260 | 260 | 258 | 258 | 210 |
Shares Outstanding | 0.5% | 62.00 | 62.00 | 62.00 | 60.00 | 60.00 | 59.00 | 59.00 | 59.00 | 59.00 | 59.00 | 58.00 | 58.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 63.00 | - | - | - | 59.00 | - | - | - | 139 | - | - | - | 126 | - | - | - | 166 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -157.4% | -12,105 | -4,702 | -7,637 | -9,833 | -10,793 | -7,239 | -8,347 | -7,428 | -8,042 | -6,951 | -4,998 | -5,977 | -6,382 | -5,414 | -8,212 | -2,604 | -4,371 | -3,759 | -1,475 | -2,330 | -3,284 |
Share Based Compensation | 21.5% | 604 | 497 | 586 | 516 | 662 | 681 | 681 | 647 | 858 | 654 | 587 | 581 | 254 | 567 | 408 | 394 | 430 | 414 | 414 | 443 | 412 |
Cashflow From Financing | 0% | 10,000 | 10,000 | 10,033 | 10,000 | 10,000 | 10,000 | - | - | - | 9,999 | 10,000 | 16,815 | - | - | - | 44.00 | 219 | 902 | -231 | 47,401 | 2,003 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 8,054 | $ 8,799 |
General and administrative | 1,594 | 1,543 |
Total operating expenses | 9,648 | 10,342 |
Total operating loss | (9,648) | (10,342) |
Other income (expense): | ||
Interest income | 80 | 44 |
Change in fair value of derivatives | (869) | (769) |
Interest expense | (1,052) | (460) |
Total other income (expense) | (1,841) | (1,185) |
Net loss | (11,489) | (11,527) |
Preferred stock dividends | (8) | 0 |
Net loss applicable to common stockholders | $ (11,497) | $ (11,527) |
Net loss per common share - basic (in dollars per share) | $ (0.19) | $ (0.19) |
Net loss per common share - diluted (in dollars per share) | $ (0.19) | $ (0.19) |
Weighted average common shares outstanding - basic (in shares) | 61,976 | 59,480 |
Weighted average common shares outstanding - diluted (in shares) | 61,976 | 59,480 |
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 23,555 | $ 25,660 |
Prepaid expenses and other current assets | 1,905 | 2,050 |
Total current assets | 25,460 | 27,710 |
Other assets | 430 | 490 |
Total assets | 25,890 | 28,200 |
Current liabilities: | ||
Accounts payable | 3,797 | 6,431 |
Accrued expenses and other | 8,836 | 9,182 |
Accrued dividends payable | 0 | 63 |
Total current liabilities | 12,633 | 15,676 |
Convertible notes payable and accrued interest, net of discounts - related party (Note 3) | 31,139 | 30,902 |
Derivative liabilities (Note 4) | 1,873 | 1,004 |
Borrowing and accrued interest under convertible line of credit, net of debt discount - related party (Notes 9 and 10) | 51,324 | 40,839 |
Other liabilities | 7 | 20 |
Total liabilities | 96,976 | 88,441 |
Commitments and contingencies (Note 11) | ||
Series C super dividend redeemable convertible preferred stock; 1,000 shares authorized, 176 shares issued and outstanding at March 31, 2024 and December 31, 2023, redemption value: $8,098,000, liquidation value: $1,760,000 at March 31, 2024 | 1,723 | 1,723 |
Stockholders' equity (deficit): | ||
Undesignated stock, $0.01 par value; 20,000,000 shares authorized, 20,000,000 designated at March 31, 2024 and December 31, 2023, respectively | 0 | 0 |
Series A 12% convertible preferred stock; 1,742,500 shares authorized, 1,235,000 issued and outstanding at March 31, 2024 and December 31, 2023, liquidation value $1,235,000 at March 31, 2024 | 500 | 500 |
Common stock, $0.001 par value; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023, 62,148,134 and 61,852,914 issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 61 | 61 |
Additional paid-in capital | 292,499 | 291,847 |
Retained deficit | (365,869) | (354,372) |
Total stockholders' equity (deficit) | (72,809) | (61,964) |
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | $ 25,890 | $ 28,200 |